The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Evaluation of SARS-CoV-2 serology assays reveals a range of test performance
Open accessAbstract
Appropriate use and interpretation of serological tests for assessments of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure, infection and potential immunity require accurate data on assay performance. We conducted a head-to-head evaluation of ten point-of-care-style lateral flow assays (LFAs) and two laboratory-based enzyme-linked immunosorbent assays to detect anti-SARS-CoV-2 IgM and IgG antibodies in 5-d time intervals from symptom onset and studied the specificity of each assay in pre-coronavirus disease 2019 specimens. The percent of seropositive individuals increased with time, peaking in the latest time interval tested (>20 d after symptom onset). Test specificity ranged from 84.3% to 100.0% and was predominantly affected by variability in IgM results. LFA specificity could be increased by considering weak bands as negative, but this decreased detection of antibodies (sensitivity) in a subset of SARS-CoV-2 real-time PCR-positive cases. Our results underline the importance of seropositivity threshold determination and reader training for reliable LFA deployment. Although there was no standout serological assay, four tests achieved more than 80% positivity at later time points tested and more than 95% specificity. Of 12 serology assays tested, four detect antibodies in more than 80% of patients with COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Virological assessment of hospitalized patients with COVID-2019
Wölfel, R., Corman, V. M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M. A., Niemeyer, D., Jones, T. C., Vollmar, P., Rothe, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2196-x · Cited by 6,661
Li, R., Pei, S., Chen, B., Song, Y., Zhang, T., Yang, W., & Shaman, J. (2020) · Science · doi:10.1126/science.abb3221 · Cited by 3,633
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Zhao, J., Yuan, Q., Wang, H., Liu, W., Liao, X., Su, Y., Wang, X., Yuan, J., Li, T., Li, J., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa344 · Cited by 2,607
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses
Jiang, S., Hillyer, C., & Du, L. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.03.007 · Cited by 847
Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2
Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1743767 · Cited by 711
What policy makers need to know about COVID-19 protective immunity
Altmann, D. M., Douek, D. C., & Boyton, R. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30985-5 · Cited by 223
Cited by
Hodgson, S. H., Mansatta, K., Mallett, G., Harris, V., Emary, K. R. W., & Pollard, A. J. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30773-8 · Cited by 633
Ortiz-Prado, E., Simbaña-Rivera, K., Gómez- Barreno, L., Rubio-Neira, M., Guaman, L. P., Kyriakidis, N. C., Muslin, C., Jaramillo, A. M. G., Barba-Ostria, C., Cevallos-Robalino, D., et al. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115094 · Cited by 458
Freeman, E. E., McMahon, D. E., Lipoff, J. B., Rosenbach, M., Kovarik, C., Desai, S. R., Harp, J., Takeshita, J., French, L. E., Lim, H. W., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.06.1016 · Cited by 409
COVID-19 diagnostics in context
Weissleder, R., Lee, H., Ko, J., & Pittet, M. J. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abc1931 · Cited by 396
Serology assays to manage COVID-19
Krammer, F., & Simon, V. (2020) · Science · doi:10.1126/science.abc1227 · Cited by 325
Metadata
- Authors
- Whitman, J. D., Hiatt, J., Mowery, C. T., Shy, B. R., Yu, R., Yamamoto, T. N., Rathore, U., Goldgof, G. M., Whitty, C., Woo, J. M., Gallman, A. E., Miller, T. E., Levine, A. G., Nguyen, D. N., Bapat, S. P., Balcerek, J., Bylsma, S. A., Lyons, A. M., Li, S., Wong, A. W.-Y., Gillis-Buck, E. M., Steinhart, Z. B., Lee, Y., Apathy, R., Lipke, M. J., Smith, J. A., Zheng, T., Boothby, I. C., Isaza, E., Chan, J., Acenas, D. D., Lee, J., Macrae, T. A., Kyaw, T. S., Wu, D., Ng, D. L., Gu, W., York, V. A., Eskandarian, H. A., Callaway, P. C., Warrier, L., Moreno, M. E., Levan, J., Torres, L., Farrington, L. A., Loudermilk, R. P., Koshal, K., Zorn, K. C., Garcia-Beltran, W. F., Yang, D., Astudillo, M. G., Bernstein, B. E., Gelfand, J. A., Ryan, E. T., Charles, R. C., Iafrate, A. J., Lennerz, J. K., Miller, S., Chiu, C. Y., Stramer, S. L., Wilson, M. R., Manglik, A., Ye, C. J., Krogan, N. J., Anderson, M. S., Cyster, J. G., Ernst, J. D., Wu, A. H. B., Lynch, K. L., Bern, C., Hsu, P. D., & Marson, A.
- Venue
- Nature Biotechnology
- Published
- 2020-08-27
- Volume
- 38
- Issue
- 10
- Pages
- 1174-1183
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W3081055927
- Cited by
- 454
- References
- 8
- FWCI
- 12.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation of SARS-CoV-2 serology assays reveals a range of test performance. https://app.cochat.ai/papers/10.1038/s41587-020-0659-0
- The paper
- Whitman, J. D., Hiatt, J., Mowery, C. T., Shy, B. R., Yu, R., Yamamoto, T. N., Rathore, U., Goldgof, G. M., Whitty, C., Woo, J. M., Gallman, A. E., Miller, T. E., Levine, A. G., Nguyen, D. N., Bapat, S. P., Balcerek, J., Bylsma, S. A., Lyons, A. M., Li, S., . . . Marson, A. (2020). Evaluation of SARS-CoV-2 serology assays reveals a range of test performance. Nature Biotechnology. https://doi.org/10.1038/s41587-020-0659-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
